Clinical Trials Logo

Clinical Trial Summary

Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasis. Objective: i) To investigate the cause of parathyroid disorders ii) To describe evolution, natural history, and longitudinal trends of parathyroid and related disorders seen in syndromic presentations like multiple endocrine neoplasia, hyperparathyroidism-jaw tumor syndrome Eligibility: People ages 6 months older who have, are at risk of having, or are related to a person with a parathyroid or related disorder. Design: Participants will be screened with a review of their medical records. Participants will be seen, tested, and treated by doctors based on their condition. Their visits may be in person or via telehealth. Participants will complete questionnaires. They will answer questions about their physical, mental, and social health. Participants may give samples such as saliva, blood, urine, or stool. Participants may give cheek cell samples. They will do this using a cheek swab or by spitting into a cup. Adult participants may give a skin biopsy. For this, a small bit of skin is removed with a punch tool. Participants may have medical photos taken. If participants have surgery during the course of their regular care either at the NIH or at a different hospital or doctor s office, researchers will ask for some of the leftover tissue. Participants will be in the study as long as they are being seen by their doctor.


Clinical Trial Description

Study Description: Patients with confirmed, suspected or at risk of developing parathyroid disorders will be provided standard of care testing for their condition. Data obtained during the testing will be used for research. Additionally, samples may be collected for research. Objectives: - To investigate the cause of the disease and its associated manifestations, possibly genetic in participants with parathyroid and related disorder(s) - To identify biomarkers of the various parathyroid disorder(s) and associated manifestations by performing molecular profiling of available biospecimens - To describe evolution, natural history and longitudinal trends of parathyroid and related disorders including the associated extra- parathyroid manifestations seen in these disorders, for example, Zollinger-Ellison syndrome, gastro-entero-pancreatic neuroendocrine tumors, kidney, jaw, pituitary and uterine tumors. - To investigate the natural history of parathyroid disorders and associated manifestations during pregnancy - To characterize the morbidity and mortality in participants with parathyroid and related disorders and investigate its association with extra-parathyroidal manifestations. - To investigate long-term risks and benefits with standard of care testing and therapy for parathyroid and associated extra-parathyroidal manifestations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04969926
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact Craig S Cochran, R.N.
Phone (301) 402-1880
Email craigc@bdg10.niddk.nih.gov
Status Recruiting
Phase
Start date November 30, 2021
Completion date January 22, 2031

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03931109 - Circulating miRNA in Primary Hyperparathyroidism
Completed NCT04305561 - Preoperative Localization Strategies in Primary Hyperparathyroidism N/A
Recruiting NCT03052075 - Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism
Completed NCT03774771 - Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism Phase 2
Recruiting NCT02854345 - Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera N/A
Completed NCT01222026 - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Phase 4
Recruiting NCT00973336 - Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery? Phase 2
Completed NCT01530919 - Minimally Invasive Radioguided Parathyroidectomy N/A
Recruiting NCT03605472 - Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism N/A
Completed NCT01306656 - Vitamin D Repletion in Primary Hyperparathyroidism Phase 4
Terminated NCT00961701 - Lipids Profile in Primary Hyperparathyroidism N/A
Completed NCT00432939 - Primary Hyperparathyroidism: Non-classical Manifestations N/A
Completed NCT00522028 - Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial N/A
Completed NCT03713671 - Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism N/A
Recruiting NCT03039439 - Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
Not yet recruiting NCT03732157 - Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients
Completed NCT01996072 - EC17 for Intraoperative Imaging for Parathyroidectomy Phase 1
Completed NCT01460030 - An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Phase 3
Enrolling by invitation NCT04085419 - Osteoporosis in Primary Hyperparathyroidism Phase 4
Recruiting NCT03935984 - Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity Phase 4